GleamWall
中文EN

BMRA BIOMERICA INC

In Vitro & In Vivo Diagnostic Substances · Nasdaq · SEC CIK 73290 · Fiscal year ends 05/31

Financial factors as of 2026-08-31 (2027Q1), TTM = sum of the last four quarters

Growth

TTM revenue YoY-11.2%
TTM net income YoY-37.0%
TTM EPS YoY-9.2%
Revenue 3-yr CAGR-7.1%
Net income 3-yr CAGR—

Margins

Gross margin0.9%
Operating margin-125.2%
Net margin-115.5%
FCF margin—
EBITDA margin-123.6%

Returns

ROE-113.8%
ROA-67.1%
ROIC (approx.)-284.4%
Asset turnover0.58x

Leverage & solvency

Liabilities / assets54.8%
Debt / equity0.00x
Current ratio1.91x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.79x
Accruals ratio-14.1%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2027Q12026-08-312026Q4*2026-05-312026Q32026-02-282026Q22025-11-302026Q12025-08-312025Q4*2025-05-312025Q32025-02-282025Q22024-11-30
Income statement
Revenue$1.26M$875,000$987,000$1.21M$1.38M$749,000$1.12M$1.64M
Cost of revenue$1.16M$946,000$1.03M$1.16M$956,000$993,000$1.10M$1.20M
Gross profit$103,000-$71,000-$44,000$51,000$424,000-$244,000$19,000$437,000
R&D expense$206,000$205,000$178,000$193,000$212,000$252,000$217,000$257,000
SG&A expense$1.12M$1.26M$1.08M$1.23M$1.33M$1.07M$1.01M$1.17M
Operating income-$1.23M-$1.53M-$1.30M-$1.37M-$1.12M-$1.56M-$1.21M-$993,000
Pretax income-$1.23M-$1.14M-$1.30M-$1.31M$5,000-$1.54M-$1.17M-$953,000
Income tax$6,000$6,000$8,000$5,000$3,000$5,000-$4,000-$3,000
Net income-$1.23M-$1.15M-$1.31M-$1.32M$2,000-$1.54M-$1.16M-$950,000
EBITDA-$1.21M-$1.52M-$1.28M-$1.35M-$1.10M-$1.54M-$1.19M-$971,000
EPS (basic)-0.37—-0.44-0.450.00—-0.48-0.06
EPS (diluted)-0.37—-0.44-0.450.00—-0.48-0.06
Weighted avg. shares (diluted)3.30M—3.01M2.91M2.64M—2.40M2.14M
Balance sheet
Cash & equivalents$2.73M$1.31M$1.34M$2.54M$3.05M$2.40M$3.06M$2.37M
Receivables$897,000$785,000$941,000$947,000$1.21M$731,000$1.27M$1.33M
Inventory$1.63M$1.71M$1.65M$1.52M$1.47M$1.49M$1.66M$1.79M
Current assets$5.41M$4.02M$4.12M$5.19M$5.90M$4.88M$6.20M$5.95M
PP&E, net$68,000$78,000$91,000$105,000$120,000$135,000$151,000$167,000
Intangibles$204,000$209,000$231,000$219,000$223,000$228,000$234,000$236,000
Total assets$8.07M$6.76M$4.88M$6.03M$6.85M$5.95M$7.38M$7.27M
Current liabilities$2.84M$2.48M$1.56M$1.60M$1.69M$1.74M$1.65M$1.88M
Total liabilities$4.42M$4.13M$1.56M$1.60M$1.70M$1.84M$1.84M$2.16M
Shareholders' equity$3.65M$2.63M$3.32M$4.43M$5.16M$4.11M$5.53M$5.11M
Shares outstanding4.60M3.20M3.03M2.95M2.82M2.55M20.37M18.34M
Cash flow statement
Operating cash flow-$802,000-$912,000-$1.25M-$991,000-$268,000-$661,000-$1.04M-$791,000
Investing cash flow—$18,000———$0-$4,000—
Financing cash flow$2.23M$871,000$61,000$482,000$920,000-$5,000$1.74M—
Depreciation & amortization$15,000$17,000$20,000$20,000$20,000$23,000$21,000$22,000
Stock-based compensation$134,000$91,000$58,000$72,000$133,000$108,000$91,000$155,000

Free plan shows the latest 8 periods; Pro shows all 65 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.